(Q28298996)

https://api.crossref.org/works/10.2146%2FAJHP090672

Antimicrobial resistance among and therapeutic options against gram-negative pathogens.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

The carbapenems: new broad spectrum beta-lactam antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Comparative pharmacokinetics of the carbapenems: clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Comparative review of the carbapenems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Recent developments in carbapenems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacteri

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

In vitro activity of doripenem against Acinetobacter baumannii clinical isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Activity of a novel carbapenem, doripenem, against anaerobic pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Antimicrobial resistance in gram-positive bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

31 March 2020

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

In vitro activity of doripenem

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Safety of intravenous infusion of doripenem.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Doripenem-induced intertriginous drug eruption as a mild form of AGEP.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Interaction between valproic acid and carbapenem antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Stability of doripenem in vitro in representative infusion solutions and infusion bags

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Compatibility of doripenem with other drugs during simulated Y-site administration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672

Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090672